Neuroscience discipline
Vigil’s TREM2-Targeted Alzheimer’s Treatment Advances to Phase II with Promising Early Results
TREM2, Alzheimer’s disease, Vigil Neuroscience, VG-3927, Phase II clinical trial, microglial-targeted therapeutics
Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification
Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration
Sage Therapeutics Files Lawsuit Against Biogen Following $469 Million Acquisition Offer
Sage Therapeutics, Biogen, lawsuit, acquisition offer, $469 million, neuroscience, pharmaceutical industry
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A
GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research
GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.
AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy
AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry
Alto Neuroscience’s Mid-Stage Depression Trial Fails, Casting Doubts on Neuropsychiatry R&D Strategy
Alto Neuroscience, depression trial, neuropsychiatry R&D, ALTO-100, biomarker strategy, clinical failure